Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16149688 | 1.00 | HCRTR2 (0.76) | HCRTR2HCRTR1 | |
| SCHEMBL16157796 | 0.92 | HCRTR2 (0.88) | HCRTR2HCRTR1 | |
| SCHEMBL16149179 | 0.92 | HCRTR2 (0.88) | HCRTR2HCRTR1 | |
| SCHEMBL18696719 | 0.90 | HCRTR2 (0.66) | HCRTR2HCRTR1 | |
| SCHEMBL16043193 | 0.88 | HCRTR2 (0.82) | HCRTR2HCRTR1 | |
| SCHEMBL16091946 | 0.88 | HCRTR2 (0.82) | HCRTR2HCRTR1 | |
| SCHEMBL16157975 | 0.87 | HCRTR1 (0.76) | HCRTR2HCRTR1 | |
| SCHEMBL17510546 | 0.87 | HCRTR1 (0.76) | HCRTR2HCRTR1 | |
| SCHEMBL16042638 | 0.86 | HCRTR1 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL16091962 | 0.86 | HCRTR1 (1.00) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272824-A2 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3622956-A1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2020-03-18 | — | — | EP | disclosed |
| US-10183953-B2 | Substituted 2-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-22 | — | — | US | disclosed |
| US-20170204096-A1 | Substituted 2-Azabicycles And Their Use As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | US | disclosed |
| US-9611277-B2 | Substituted 2-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
| WO-2014165070-A1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183953-B2 | Substituted 2-azabicycles and their use as orexin receptor modulators | HCRTR2, HCRTR1, NPY2R | HCRTR2 1/4885HCRTR1 2/4885 |
| US-20170204096-A1 | Substituted 2-Azabicycles And Their Use As Orexin Receptor Modulators | HCRTR2, HCRTR1, NPY2R | HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.